Seattle Genetics conjugates with immuno-oncology upstart Unum in $645M deal

Just 8 months after gathering together a $12 million A round to get started with its own twist on adaptive T-cell technology, Cambridge, MA-based Unum Therapeutics has teamed up with Seattle Genetics in a $645 million immuno-oncology deal designed to marry some finely tuned antibody drug conjugate technology with the latest in cancer-fighting R&


Comments are closed.